U.S. FDA approves AbbVie all-oral hepatitis C treatment
December 19, 2014 at 15:02 PM EST
Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus.
